Drug Trial Radar · NCT05355402
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
May 9, 2022
Primary completion
Mar 22, 2023
Study completion Dec 21, 2023
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- May 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG. Other objectives were to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).
Conditions
- Hypertriglyceridemia
- Atherosclerotic Cardiovascular Disease
- Severe Hypertriglyceridemia
Interventions
OlezarsenDrug
SC injection.
PlaceboDrug
SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Fasting TG at Month 6Time frame: Baseline, Month 6
Locations
24 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Trials Research
Lincoln, California
Catalina Research Institute, LLC
Montclair, California
Excel Medical Clinical Trials, LLC
Boca Raton, Florida
De La Cruz Research Center
Miami, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Research Physicians Network Alliance
Winter Park, Florida
IACT Health
Columbus, Georgia
Evanston Premier Healthcare Research
Evanston, Illinois
Clinical Investigation Specialist
Gurnee, Illinois
West Broadway Clinic
Council Bluffs, Iowa
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Louisville, Kentucky
Aa Mrc, Llc
Flint, Michigan
Clinical Research of South Nevada
Las Vegas, Nevada
Palm Research Center, Inc.
Las Vegas, Nevada
Green and Seidner Family Practice Associates
Lansdale, Pennsylvania
Main Street Physicians Care Waterway
Little River, South Carolina
Health Concepts
Rapid City, South Dakota
Tennessee Center for Clinical Trials
Tullahoma, Tennessee
Southern Endocrinology Associates
Mesquite, Texas
Manassas Clinical Research Center
Manassas, Virginia
York Clinical Research LLC
Norfolk, Virginia
Clinique des Maladies Lipidiques de Quebec Inc.
Québec, Canada
Bluewater Clinical Research Group Inc
Sarnia, Ontario, Canada
Ecogene-21
Chicoutimi, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.